<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03506399</url>
  </required_header>
  <id_info>
    <org_study_id>16004</org_study_id>
    <secondary_id>I8D-MC-AZEK</secondary_id>
    <nct_id>NCT03506399</nct_id>
  </id_info>
  <brief_title>A Study of Lanabecestat in Healthy Female Participants Taking Oral Contraceptive</brief_title>
  <official_title>Effect of Lanabecestat on the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel in Healthy Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the effect of oral contraceptive (birth control pill) on the blood
      level of lanabecestat when both are given together. Side effects will be monitored and
      documented. This study will last up to 27 days for each participant, not including screening.
      Screening is required within 42 days prior to first dose.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 14, 2018</start_date>
  <completion_date type="Anticipated">October 19, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 19, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under The Concentration Curve (AUC) of Ethinyl Estradiol</measure>
    <time_frame>Baseline though 120 hours after administration of the study drug (lanabecestat)</time_frame>
    <description>PK: AUC of Ethinyl Estradiol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: AUC of Levonorgestrel</measure>
    <time_frame>Baseline though 120 hours after administration of the study drug (lanabecestat)</time_frame>
    <description>PK: AUC of Levonorgestrel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Observed Concentration (Cmax) of Ethinyl Estradiol</measure>
    <time_frame>Baseline though 120 hours after administration of the study drug (lanabecestat)</time_frame>
    <description>PK: Cmax of Ethinyl Estradiol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Cmax of Levonorgestrel</measure>
    <time_frame>Baseline though 120 hours after administration of the study drug (lanabecestat)</time_frame>
    <description>PK: Cmax of Levonorgestrel</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Oral Contraceptive (OC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ethinyl estradiol and levonorgestrel administered as a single dose, orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lanabecestat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of lanabecestat</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lanabecestat and OC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral dose of oral contraceptive and single daily doses of lanabecestat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanabecestat</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Lanabecestat</arm_group_label>
    <arm_group_label>Lanabecestat and OC</arm_group_label>
    <other_name>LY3314814</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Contraceptive</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Oral Contraceptive (OC)</arm_group_label>
    <arm_group_label>Lanabecestat and OC</arm_group_label>
    <other_name>Ethinyl Estradiol and Levonorgestrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are healthy female participants

          -  Women not of childbearing potential; women of childbearing potential using a
             non-hormonal intrauterine device (IUD)

          -  Have a body mass index (BMI) of 17.5 to 32 kilogram per meter square (kg/m²)

        Exclusion Criteria:

          -  Have a history of or current significant ophthalmic disease, which includes
             participants with clinically significant eye abnormalities, particularly any eye
             problem involving the retina, as determined by the investigator

          -  Have vitiligo or any other clinically significant disorder of skin or hair
             pigmentation, as determined by the investigator

          -  Have a history of or current neuropsychiatric disease/condition including psychosis,
             affective disorder, anxiety disorder, borderline state, or personality disorder
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1‐877‐CTLILLY (1‐877‐285‐4559) or 1‐317‐615‐4559 Mon ‐ Fri 9 AM ‐ 5 PM Eastern time (UTC/GMT ‐ 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>This is a single site clinical trial. 1‐877‐CTLILLY (1‐877‐285‐4559) or</last_name>
    <phone>1‐317‐615‐4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1‐877‐CTLILLY (1‐877‐285‐4559, 1‐317‐615‐4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT ‐ 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <zip>138623</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eli Lilly and Company</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2018</study_first_submitted>
  <study_first_submitted_qc>April 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2018</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

